HomeAI · summaries
Storia in 4 fonti
Pfizer's good-enough obesity data in a crowded market may force competition on price, dosing
Pfizer's berobenatide shows up to 10.2% weight loss and 2.2% blood sugar reduction in Phase 2b trial in patients with obesity and type 2 diabetes.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Detailed data show Pfizer’s monthly obesity drug continues to show potential
Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.
- ·
endpoints.news
Pfizer's good-enough obesity data in a crowded market may force competition on price, dosing
Pfizer's berobenatide shows up to 10.2% weight loss and 2.2% blood sugar reduction in Phase 2b trial in patients with obesity and type 2 diabetes.
- ·
thehindubusinessline.com
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial
Pfizer's monthly obesity shot, berobenatide, shows similar side effects to Wegovy, aiming for differentiation in the weight-loss market.
- ·
healio.com
Berobenatide shows promise for monthly GLP-1 dosing
NEW ORLEANS — New data from three phase 2b studies demonstrate substantial weight loss with berobenatide, an ultralong-acting GLP-1 receptor agonist, in people with obesity or…
- ·
Nearly 1 in 5 patients quit Boehringer and Zealand’s obesity shot over side effects
Boehringer's survodutide showed 19% GI discontinuation rates in a Phase 3 obesity trial but was on par with Wegovy on weight loss.
- ·
AstraZeneca's obesity pill matches rivals in Phase 2, anchoring $5B franchise push
AstraZeneca's oral GLP-1 elecoglipron cut weight up to 10.5% in Phase 2, as AZ launches multiple Phase 3 trials targeting a $5B obesity franchise.